This article reviews the challenges of fasting and dietary regimens in producing sustained weight loss and reports no new research findings or results.
83 citations
,
March 2015 in “International Journal of Dermatology”
This retrospective study found that adipose-derived stem cell-conditioned media increased hair density and thickness in women with female pattern hair loss over 12 weeks, with no severe adverse effects reported.
66 citations
,
October 1987 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism”
This study found that serum 3 alpha-diol G levels in women with idiopathic hirsutism correlated well with their clinical response to treatment, suggesting its usefulness in evaluating treatment outcomes.
This article reviews the role and clinical applications of 1,25-dihydroxyvitamin D3 and parathyroid hormone-related peptide in dermatology, with a focus on psoriasis treatment, and reports no new experimental findings.
3 citations
,
January 2001 in “Cambridge University Press eBooks”
This review discusses the role of androgens in male sexual differentiation and characteristics and reports no new clinical results; it emphasizes the androgen dependence of male pattern scalp hair loss.
Can I use clascoterone if I'm undergoing gender-affirming hormone therapy?No published clinical trial has tested clascoterone in people on gender-affirming hormone therapy, so its safety in that group is unknown. The FDA label reports low systemic exposure and no described effect on blood testosterone, but it also records HPA-axis suppression and raised potassium in a small minority of subjects.
Is Fluridil only for men with androgenetic alopecia, or can women use it too?The only published clinical study of fluridil enrolled 43 men, so its use in women is untested rather than established; women considering it should talk to a doctor, and it is not advised in pregnancy or breastfeeding because no reproductive-safety data exists.
Is metformin used topically for hair loss, or only as an oral tablet?Approved metformin products are oral tablets only; there is no approved topical metformin for hair loss. Published human reports of topical use are a handful of uncontrolled, pharmacy-compounded case reports in scarring alopecia, and the most-cited clinical series actually used the oral drug.
A clinical trial in Australia offers $20,000 for participation, aiming to regrow hair and reverse grey hair. Participants must not have used hair treatments recently and must visit a Melbourne clinic regularly over 18 months.
Verteporfin is being discussed for its potential to regrow hair and heal scars, possibly aiding hair transplants or replacing them. Some users are skeptical about its effectiveness, while others suggest combining it with microneedling for better results.
The conversation is about a user considering joining a clinical study for Clascoterone (Breezula) after experiencing no results with topical finasteride and minoxidil, and side effects from oral finasteride. The user is seeking advice on clinical study participation and experiences.
A user created a tracker for hair loss treatments in clinical development, including compounds like Dermaliq, RU58841, and Pyrilutamide. The tracker updates with new information and allows filtering by conditions like androgenetic alopecia (AGA) and alopecia areata (AA).
The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.